Sintilimab is a highly selective programmed cell death protein 1 (PD-1) immune checkpoint inhibitor (ICI), which can block the PD-1/PD-L1 signaling pathway, thereby activating the immune system and enhancing its ability to recognize and kill tumor cells. The gene discussed is PDCD1; the disease is neoplasm.